Finland’s Orion Corp has entered into a licensing agreement with digital therapeutics (DTx) specialist Newel Health, handing over rights to an app designed to support pati
Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to be the first prostate cancer treatment to be mad
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.